Am J Clin Nutr. 1992 Jan;55(1 Suppl):309S-313S.

Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin).

Source

Hoffmann-La Roche Inc, Nutley, NJ 07110-1199.

Abstract

Excessive intake of dietary fat contributes to the development and maintenance of both obesity and hyperlipidemia. Inhibition of gastrointestinal lipases could decrease the amount of ingested fat that is absorbed systemically by preventing the hydrolysis of triglycerides. Ro 18-0647, a chemically synthesized derivative of the natural product lipstatin, inhibits the action of gastrointestinal lipases. Initial studies in humans have shown that Ro 18-0647 can reliably increase fecal fat excretion. Ro 18-0647 has also been shown to be well tolerated in the majority of normal volunteers and obese patients studied. Further research must be conducted to determine whether clinical endpoints of weight loss or cholesterol lowering can be produced by using this new pharmacologic principle.

PMID:: 1728845; [PubMed - indexed for MEDLINE]

Free full text

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Molecular Biology Databases

ORLISTAT - HSDB

Supplemental Content

Save items

Related citations in PubMed

Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase. [Int J Obes. 1987]
Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase.
Hogan S, Fleury A, Hadvary P, Lengsfeld H, Meier MK, Triscari J, Sullivan AC. Int J Obes. 1987; 11 Suppl 3:35-42.
Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. [J Antibiot (Tokyo). 1987]
Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity.
Weibel EK, Hadvary P, Hochuli E, Kupfer E, Lengsfeld H. J Antibiot (Tokyo). 1987 Aug; 40(8):1081-5.
Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. [Br J Clin Pharmacol. 2009]
Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers.
Bryson A, de la Motte S, Dunk C. Br J Clin Pharmacol. 2009 Mar; 67(3):309-15. Epub 2008 Sep 19.
Review Mode of action of orlistat. [Int J Obes Relat Metab Disord....]
Review Mode of action of orlistat.
Guerciolini R. Int J Obes Relat Metab Disord. 1997 Jun; 21 Suppl 3:S12-23.
Review Orlistat, a new lipase inhibitor for the management of obesity. [Pharmacotherapy. 2000]
Review Orlistat, a new lipase inhibitor for the management of obesity.
Heck AM, Yanovski JA, Calis KA. Pharmacotherapy. 2000 Mar; 20(3):270-9.

See reviews... See all...

Cited by 2 PubMed Central articles

The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents. [Diabetes Metab Syndr Obes. 2010]
The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents.
Tucci SA, Boyland EJ, Halford JC. Diabetes Metab Syndr Obes. 2010 May 10; 3:125-43. Epub 2010 May 10.
Pharmacological treatment of obesity in children and adolescents: present and future. [J Obes. 2011]
Pharmacological treatment of obesity in children and adolescents: present and future.
Iughetti L, China M, Berri R, Predieri B. J Obes. 2011; 2011:928165. Epub 2010 Dec 15.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18...
Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin).
Am J Clin Nutr. 1992 Jan ;55(1 Suppl):309S-313S.

PubMed
Critical importance of length-scale dependence in implicit modeling of hydrophob...
Critical importance of length-scale dependence in implicit modeling of hydrophobic interactions.
J Am Chem Soc. 2007 Mar 7 ;129(9):2444-5. Epub 2007 Feb 9 .

PubMed
A brief overview of human energy metabolism and its relationship to essential ob...
A brief overview of human energy metabolism and its relationship to essential obesity.
Am J Clin Nutr. 1992 Jan ;55(1 Suppl):242S-245S.

PubMed
Chronic Myeloid Leukaemia in The 21st Century.
Chronic Myeloid Leukaemia in The 21st Century.
Ulster Med J. 2007 Jan ;76(1):8-17.

PubMed
[Environmental tobacco smoke exposure in pregnancy and postpartum period].
[Environmental tobacco smoke exposure in pregnancy and postpartum period].
Przegl Lek. 2006 ;63(10):907-10.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: